Aeronid HFA
৳ 410.00
Inhalation/Respiratory:
Asthma-
Adult: As metered-dose aerosol: 400 mcg daily in 2 divided doses, increased up to 1.6 mg daily in severe cases. Maintenance: 200-400 mcg daily. As dry powd inhaler: 200-800 mcg daily in single dose or in 2 divided doses. Max: 800 mcg bid. As nebuliser soln: Severe asthma: 1-2 mg bid. Maintenance dose: 0.5-1 mg bid.
Child: 2-12 yr As metered-dose aerosol: 200-800 mcg daily in divided doses. 5-12 yr As dry powd inhaler: 200-800 mcg daily in 2 divided doses. 3 mth to 12 yr As nebuliser soln: Initially, 0.5-1 mg bid. Maintenance dose: 0.25-0.5 mg bid.
Inhalation/Respiratory:
Croup-
Child: As nebuliser soln: 2 mg as a single dose or as 2 doses of 1 mg w/ 30 min interval, may be repeated 12 hrly for a max of 36 hr or until clinical improvement is observed.
Nasal:
Nasal polyps-
Adult: As metered-dose spray (64 mcg or 100 mcg/dose): 1 spray into each nostril bid up to 3 mth; alternatively, 2 sprays into each nostril once daily for preparations containing 64 mcg/dose.
Child: ≥6 yr Same as adult dose.
Nasal:
Allergic rhinitis-
Adult: As metered-dose spray (64 mcg or 100 mcg/dose): Initially, 2 sprays into each nostril daily or 1 spray into each nostril bid, reduce to 1 spray into each nostril daily until symptoms are controlled.
Child: ≥6 yr Same as adult dose.
Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. The precise mechanism of corticosteroid actions on inflammation in asthma, Crohn’s disease, or ulcerative colitis is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic and non-allergic-mediated inflammation. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in the aforementioned diseases. Because budesonide undergoes significant first-pass elimination, the both oral preparations are formulated as an extended release tablet. As a result, budesonide release is delyaed until exposure to a pH ≥ 7 in the small intestine.
Related products
